Spyre Therapeutics (NASDAQ:SYRE) Reaches New 12-Month High on Analyst Upgrade

Spyre Therapeutics, Inc. (NASDAQ:SYRE) shares hit a new 52-week high on Monday after Robert W. Baird raised their price target on the stock from $65.00 to $90.00. Robert W. Baird currently has an outperform rating on the stock. Spyre Therapeutics traded as high as $75.00 and last traded at $65.3690, with a volume of 1256982 shares traded. The stock had previously closed at $51.29.

Several other research analysts have also commented on the stock. Wells Fargo & Company boosted their price objective on shares of Spyre Therapeutics from $50.00 to $90.00 and gave the stock an “overweight” rating in a research note on Tuesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Spyre Therapeutics in a research note on Monday, December 29th. Citigroup started coverage on shares of Spyre Therapeutics in a research note on Wednesday, December 17th. They set a “buy” rating and a $64.00 price objective for the company. Raymond James Financial started coverage on shares of Spyre Therapeutics in a research note on Monday. They set a “strong-buy” rating and a $80.00 price objective for the company. Finally, Stifel Nicolaus boosted their price objective on shares of Spyre Therapeutics from $70.00 to $92.00 and gave the stock a “buy” rating in a research note on Wednesday, March 18th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $82.50.

Insider Buying and Selling

In related news, insider Sheldon Sloan sold 7,958 shares of the business’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $50.00, for a total transaction of $397,900.00. Following the completion of the transaction, the insider owned 7,958 shares in the company, valued at $397,900. The trade was a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott L. Burrows sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $49.34, for a total transaction of $370,050.00. Following the transaction, the chief financial officer owned 97,994 shares in the company, valued at $4,835,023.96. The trade was a 7.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 62,958 shares of company stock worth $2,734,375 in the last 90 days. 6.20% of the stock is owned by corporate insiders.

More Spyre Therapeutics News

Here are the key news stories impacting Spyre Therapeutics this week:

• Positive Sentiment: Top-line SPY001 Part A (SKYLINE) Phase 2 induction data show rapid, deep efficacy and a clean safety profile — 9.2‑point RHI reduction, ~40% clinical remission and ~51% endoscopic improvement at 12 weeks, claims best‑in‑class potential. Reuters: Spyre’s inflammatory bowel drug shown to reduce disease activity in mid-stage study
• Positive Sentiment: Company press release highlights statistically significant primary endpoint and frames SPY001 as “potential best‑in‑class,” underpinning upside for commercial and combination-regimen value. GlobeNewswire: SPY001 Part A Induction Results
• Positive Sentiment: Multiple sell‑side firms raised targets and ratings after the data: Leerink to $106 (Outperform), BTIG to $98 (Buy), and Robert W. Baird to $90 (Outperform) — these upgrades increase upside expectations and buy‑side interest. Benzinga: Analyst Price Target Raises
• Positive Sentiment: Analyst/market commentary (Seeking Alpha) frames the SPY001 dataset as a catalyst-rich setup for 2026 with valuation implying high expectations for mono and combination uses. Seeking Alpha: Strong SPY001 Data
• Neutral Sentiment: Trading was briefly halted early on the news (“news pending”), a common step around material corporate/clinical announcements; the halt has ended and normal trading resumed. Trading Halt Notice
• Negative Sentiment: Spyre launched an underwritten public offering to raise $300M of common stock (with a 30‑day option for an additional $45M), which creates near‑term dilution risk and may pressure the share price. GlobeNewswire: Proposed Public Offering
• Negative Sentiment: Market reaction was mixed: coverage notes an immediate sell‑off tied to the offering announcement, reflecting investor sensitivity to dilution despite the strong clinical readout. Investing.com: Stock Falls on $300M Offering

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Optimize Financial Inc increased its stake in Spyre Therapeutics by 1.5% during the 4th quarter. Optimize Financial Inc now owns 25,331 shares of the company’s stock valued at $830,000 after purchasing an additional 364 shares in the last quarter. Mercer Global Advisors Inc. ADV increased its stake in Spyre Therapeutics by 0.5% during the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 106,664 shares of the company’s stock valued at $1,788,000 after purchasing an additional 522 shares in the last quarter. California State Teachers Retirement System increased its stake in Spyre Therapeutics by 1.8% during the 2nd quarter. California State Teachers Retirement System now owns 33,201 shares of the company’s stock valued at $497,000 after purchasing an additional 603 shares in the last quarter. AQR Capital Management LLC increased its stake in Spyre Therapeutics by 4.5% during the 4th quarter. AQR Capital Management LLC now owns 17,820 shares of the company’s stock valued at $584,000 after purchasing an additional 773 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH increased its stake in Spyre Therapeutics by 1.1% during the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 110,456 shares of the company’s stock valued at $1,851,000 after purchasing an additional 1,172 shares in the last quarter. Institutional investors and hedge funds own 80.39% of the company’s stock.

Spyre Therapeutics Stock Performance

The firm has a market cap of $5.04 billion, a price-to-earnings ratio of -30.77 and a beta of 2.93. The stock’s 50 day simple moving average is $43.04 and its 200-day simple moving average is $33.08.

Spyre Therapeutics (NASDAQ:SYRE) last issued its quarterly earnings results on Thursday, February 19th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.04). On average, analysts expect that Spyre Therapeutics, Inc. will post -4.46 EPS for the current fiscal year.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.